Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs

21 Mar 2025

Abstract excerpt

Abstract Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (Her2−) breast cancer (BC) patients, can be effectively targeted with the alpha isoform-specific PI3K inhibitor Alpelisib. This treatment significantly improves outcomes for HR+, Her2−, and PIK3CA-mutated metastatic BC patients. However, acquired resistance, often due to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Metabolism, Diabetes, and Cancer
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40113784
DOI: 10.1038/s41392-025-02180-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting PI3K inhibitor resistance in breast cancer with metabolic drugsPMID 40113784Read ↗

mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerabilitySemantic proximity Read ↗

Genomic Alterations in PIK3CA -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα InhibitorsSemantic proximity Read ↗

PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.Semantic proximity Read ↗

The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancerSemantic proximity Read ↗

Therapeutic targets in cancer cell metabolism and autophagySemantic proximity Read ↗

Multiomics Integration Elucidates Metabolic Modulators of Drug Resistance in LymphomaSemantic proximity Read ↗

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.Semantic proximity Read ↗

Omics Analysis of Chemoresistant Triple Negative Breast Cancer Cells Reveals Novel Metabolic VulnerabilitiesSemantic proximity Read ↗

Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.Semantic proximity Read ↗

Targeting AMPK for Cancer Therapy: Metabolic Reprogramming as a Therapeutic StrategySemantic proximity Read ↗

Targeting ferroptosis resistance resensitizes metastatic HR + HER2 − breast cancer cells to palbociclib‐hormone therapySemantic proximity Read ↗

A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.